CRB supports research and research training concerning:
- Effects of contraception on human health
- New and improved methods of human contraception
- CRB co-sponsors the following Multipurpose Prevention Technologies funding opportunities:
- PAR-23-180: Next Generation Multipurpose Prevention Technologies (R01 Clinical Trial Optional)
- PAR-21-298: Multipurpose Prevention Technology: Novel Systemic Options for Young Adults (R41/R42 Clinical Trial Not Allowed)
- PAR-21-297: Multipurpose Prevention Technology: Novel Systemic Options for Young Adults (R43/R44 Clinical Trial Not Allowed)
- Get to Know NICHD! Learn more about what inspired CRB Chief Dr. Dan Johnston to pursue science and how his decisions and experiences led him to his career with NICHD.
- Physiomimetics and Organoids for Reproductive Health. At this workshop, held September 23-24, 2021, multidisciplinary experts on physiomimetics, sometimes called “organs-on-a-chip,” and organoids—complex, self-organized 3D-cell culture models that derive from stem/progenitor cells and maintain tissue-like architecture and structure—discussed applications of these technologies for reproductive health research. Access recordings from Day 1 and Day 2 , or the meeting summary (PDF 469 KB) for additional information.
- Recent publications from CRB researchers include the following:
- A brief history and future prospects of contraception. Reviews the history of contraception, shortcomings in contraceptive methods, promising approaches for male and female contraception, and simultaneous protection against unintended pregnancy and sexually transmitted infections. (PMID: 37053322)
- The urgent need for innovation in contraception. Describes the need for new contraceptive methods, the opportunities provided by research advancements, the research strategies that help advance innovative novel methods, the value of drug development accelerators, and the need for industry involvement to provide greater reproductive autonomy for everyone globally. (PMID: 36780138)
- Biomarkers and diagnostics will play essential roles in advancing innovative contraception. Discusses the current need for biomarkers and diagnostics in developing contraceptives and suggests how the field can work together to overcome clinical development challenges and regulatory approval obstacles and allow new discoveries to advance from research to use. (PMID: 35909549)
- Preclinical contraceptive development for men and women. Reviews preclinical development of non-hormonal contraceptives. (PMID: 32561907)